Keywords: Bristol-Myers Squibb, Pfizer, Bayer, Johnjon & Johnson, Apixaban, Rivaroxaban, Xareltom Stroke, DVT
Two blockbuster potential stroke/DVT drugs report good results at ESC Congress: Bristol-Myers/Pfizer’s apixaban and Bayer/J&J’s rivaroxaban
Article | 01 September 2010
Presentations as the European Cardiology Society meeting taking place in Stockholm, Sweden, showed encouraging late-stage results for two drug candidates ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
